Toripalimab
Based on 1 Customer Validation
Toripalimab is a selective, recombinant, humanized monoclonal antibody against PD-1. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.30%
- CAS 番号: 1924598-82-2
- 分子量:147.3 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
Human IgG4 kappa
Human
PDCD1/PD-1/CD279
Toripalimab specifically binds to PD-1 (EC50 21 nmol/L) and inhibits binding of PD-1 to PD-L1 [IC50 3.0 nmol/L (≈ 0.5 μg/mL)] and PD-L2 (IC50 3.1 nmol/L) in 293F cells transfected with PD-1 plasmids[2].
Toripalimab (0.01–10 μg/mL) dose-dependently promotes human T-cell proliferation[2].
Toripalimab promotes interferon-γ and TNF-α secretion in activated human peripheral blood mononuclear cell (PBMC)-derived T cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:A genetically modified mouse strain with human PD-1 knocked in (were subcutaneously inoculated with 1 × 106 MC38 cells)[3]
-
Dosage:0.3, 1, 3, 10 mg/kg
-
Administration:Intraperitoneal injection (i.p.); twice a week, total 6 times
-
Result:Inhibition of tumor growth was observed in a dose-dependent manner with substantial antitumor efficacy in 1, 3, and 10 mg/kg treatment groups. Decreased significantly at the end of the observation period (day 23)
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG4 kappa
ELISA, FACS, Functional assay
-
Immobilized PD-1 Protein, Human (143a.a, HEK293, His, HY-7396) can bind Toripalimab. The EC50 for this effect is 7.504 ng/mL. -
Flow cytometric analysis of 1X106 10 ng/mL PMA and 1 μg/mL Ionomycin co-stimulated Jurkat cells(24h) labeling Toripalimab (HY-P9978, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 kappa (HY-P99003, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
化学情報
-
CAS 番号 1924598-82-2
-
性状 Liquid
-
分子量 147.3 kDa
-
Color Colorless to light yellow
-
SMILES
[Toripalimab]
-
別名
JS-001
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
-
データシート (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
[1]. Lin Zhang, et al. Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China. Front Immunol. 2022 Jan 12;12:730666. [Content Brief]
[2]. Keam SJ. Toripalimab: First Global Approval. Drugs. 2019 Apr;79(5):573-578. [Content Brief]
[3]. Liu H, et al. Glycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy. MAbs. 2019 May/Jun;11(4):681-690. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)